83 related articles for article (PubMed ID: 3742065)
1. Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
Lønning PE; Kvinnsland S; Thorsen T; Ekse D
Breast Cancer Res Treat; 1986; 7 Suppl():S77-82. PubMed ID: 3742065
[TBL] [Abstract][Full Text] [Related]
2. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
Levin J; Markham MJ; Greenwald ES; O'Connor JF; Zumoff B; Fukushima DK
Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
[TBL] [Abstract][Full Text] [Related]
3. Relationship between urine and plasma estrogen ratios.
Longcope C; Pratt JH
Cancer Res; 1978 Nov; 38(11 Pt 2):4025-8. PubMed ID: 698950
[TBL] [Abstract][Full Text] [Related]
4. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Lønning PE; Kvinnsland S; Thorsen T; Ueland PM
Clin Pharmacokinet; 1987 Dec; 13(6):393-406. PubMed ID: 3436111
[TBL] [Abstract][Full Text] [Related]
5. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
6. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
7. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Geisler J; Lundgren S; Berntsen H; Greaves JL; Lønning PE
J Clin Endocrinol Metab; 1998 Aug; 83(8):2687-93. PubMed ID: 9709932
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
10. Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1980 Sep; 51(3):473-7. PubMed ID: 6773974
[TBL] [Abstract][Full Text] [Related]
11. Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels.
Carlström K; Pousette A; Rannevik G; Sköldefors H; Theve NO; Wilking N
Breast Cancer Res Treat; 1986; 7 Suppl():S107-9. PubMed ID: 2943337
[No Abstract] [Full Text] [Related]
12. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
13. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of oestradiol, oestrone, oestrone sulfate and "conjugated oestrogens" after oral administration.
Schindler AE; Bolt HM; Zwirner M; Hochlehnert G; Göser R
Arzneimittelforschung; 1982; 32(7):787-91. PubMed ID: 6289846
[TBL] [Abstract][Full Text] [Related]
15. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.
Lønning PE; Johannessen DC; Thorsen T; Ekse D
J Steroid Biochem; 1989 Oct; 33(4A):541-5. PubMed ID: 2811363
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide.
Lønning PE; Skulstad P
J Steroid Biochem; 1989 Oct; 33(4A):565-71. PubMed ID: 2811366
[TBL] [Abstract][Full Text] [Related]
17. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
19. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis.
Schmidt M; Hartung R; Capellino S; Cutolo M; Pfeifer-Leeg A; Straub RH
Arthritis Rheum; 2009 Oct; 60(10):2913-22. PubMed ID: 19790073
[TBL] [Abstract][Full Text] [Related]
20. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Samojlik E; Santen RJ; Wells SA
J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
